Sumatriptan Nasal Spray · 2 active FDA presentation rows for this drug
Brand: SUMATRIPTAN
FDA lists Sumatriptan Nasal Spray as To Be Discontinued (Prasco Laboratories).
No availability text on this FDA row.
Sumatriptan Nasal Spray: To Be Discontinued
FDA availability text is not recorded on this row. 2 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Sumatriptan Nasal Spray
- Manufacturer
- Prasco Laboratories
- Dosage Form
- Nasal Spray
- Presentation
- Imitrex, Nasal Spray, 20 mg/100 uL (NDC 66993-082-69)
- Package NDC
- 66993-082-69
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Sep 8, 2025
- Last Updated
- Sep 8, 2025
- Therapeutic Category
- Neurology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.
Full Drug Profile
sumatriptan
Side effects, interactions, warnings & more
Nearby, Other Sumatriptan Shortage Records
FDA reason on file: This product discontinuation is a business-related decision. General shortage guidance lives on the tracker hub.